ADx and Fujirebio Join Forces with Biogen and Beckman Coulter to Advance Alzheimer’s Diagnostics

ADx, together with Fujirebio, is excited to announce a new collaboration with Biogen and Beckman Coulter to identify and develop blood-based biomarkers for tau pathology in Alzheimer’s disease (AD). This partnership aims to enhance the early detection and diagnosis of AD, potentially leading to new clinical tests.

By combining our expertise, we hope to bring innovative diagnostic solutions to market, supporting better patient care in the fight against Alzheimer’s.

Click the button below to read the full press release!